Genmab — April 2019
-
-
Pæne store spring op og ned i kurseni slutauktionen.
-
God morgen
-
God morgen
-
"Based on the promising preliminary results and the large interest in treating RRMM patients with melflufen together with daratumumab, Oncopeptides is planning to start a phase 3 study with this combination later this year."
https://finance.yahoo.com/news/oncopeptides-provides-guidance-patient-recruitment-054600203.html -
-
well, they are already looking for an
Associate Director, Isatuximab Global Marketing, Multiple Myeloma https://www.linkedin.com/jobs/view/associate-director-isatuximab-global-marketing-multiple-myeloma-at-sanofi-1228850133?trk=guest_job_details_job_title
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind